FLT3 inhibitors in acute myeloid leukemia

RNA-basedFLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML

(2018) David G. J. Cucchi et al.   BLOOD

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

(2018) Li Xuan et al.   CANCER

Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia

(2018) Ye He et al.   CANCER LETTERS

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship

(2018) Tao Liu et al.   CTS-Clinical and Translational Science

Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines

(2018) Neetu Dayal et al.   Future Medicinal Chemistry

CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib

(2018) Hardikkumar Jetani et al.   LEUKEMIA

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

(2018) Nimitha R Mathew et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow

(2018) Andrzej Lange et al.   PLoS One

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death

(2018) Amanda Tomie Ouchida et al.   Cell Death & Disease

Clinical Profile of Gilteritinib in Japanese Patients with Relapsed/Refractory AML: an Open-Label Phase 1 Study

(2018) Kensuke Usuki et al.   CANCER SCIENCE

Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

(2017) S.K. Metzelder et al.   EUROPEAN JOURNAL OF CANCER

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

(2017) Masamichi Mori et al.   INVESTIGATIONAL NEW DRUGS

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia

(2017) Ya-Zhen Qin et al.   Journal of Hematology & Oncology

Clinical trials of CAR-T cells in China

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Emerging therapies for acute myeloid leukemia

(2017) Caner Saygin et al.   Journal of Hematology & Oncology

Recent developments in immunotherapy of acute myeloid leukemia

(2017) Felix S. Lichtenegger et al.   Journal of Hematology & Oncology

The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model

(2017) Yueh-Chwen Hsu et al.   Journal of Hematology & Oncology

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia

(2017) Hubert Hackl et al.   Journal of Hematology & Oncology

Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia

(2017) Yan Li et al.   Journal of Hematology & Oncology

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

(2017) Mingxue Fan et al.   Journal of Hematology & Oncology

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

(2017) Alexander E Perl et al.   LANCET ONCOLOGY

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crivello P, Heinold A, Rebmann V, et al. Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT. Blood. 2016;128(1):120-129.

(2016)   BLOOD

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

(2016) Steven Knapper et al.   BLOOD

Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes

(2016) Ali J. Mahdi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission

(2016) Andrew M. Brunner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)

(2016) Jeng-Wei Lu et al.   CANCER LETTERS

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

(2016) Todd M. Cooper et al.   CLINICAL CANCER RESEARCH

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

(2016) M. Ruella et al.   CLINICAL CANCER RESEARCH

Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia

(2016) Alison R. Walker et al.   LEUKEMIA & LYMPHOMA

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor

(2016) John M. Hatcher et al.   ACS Medicinal Chemistry Letters

Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation

(2015) A. Tschan-Plessl et al.   ANNALS OF HEMATOLOGY

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activatingFLT3mutations

(2015) Walter Fiedler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia

(2015) Monica R. Muppidi et al.   Clinical Lymphoma Myeloma & Leukemia

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis

(2015) Elizabeth O. Hexner et al.   LEUKEMIA & LYMPHOMA

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

(2014) H. Ma et al.   BLOOD

G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia

(2014) H. K. Lee et al.   BLOOD

Treatment with FLT3 inhibitor in patients withFLT3-mutated acute myeloid leukemia is associated with development of secondaryFLT3-tyrosine kinase domain mutations

(2014) Yesid Alvarado et al.   CANCER

FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia

(2014) H. S. Ma et al.   CANCER RESEARCH

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

(2014) Giridharan Ramsingh et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3

(2014) Zhihong Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

(2014) K. Keegan et al.   MOLECULAR CANCER THERAPEUTICS

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia

(2013) E. I. Zimmerman et al.   BLOOD

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia

(2013) S. D. Baker et al.   CLINICAL CANCER RESEARCH

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

(2013) Kerstin Maria Kampa-Schittenhelm et al.   Molecular Cancer

Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells

(2012) Chieh-Lin Jerry Teng et al.   ANNALS OF HEMATOLOGY

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

(2012) R M Stone et al.   LEUKEMIA

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

(2011) Marcus M. Schittenhelm et al.   CELL CYCLE

Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation

(2010) Wei Zhao et al.   ANTI-CANCER DRUGS

How I treat acute myeloid leukemia

(2010) J. M. Rowe et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD